MDT-AP-1239
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 3.96
- os_event
- true
- age_years
- 2
- sex
- M
- new_clusters
- C3
- umap1_2d
- 4.559201018
- umap2_2d
- 3.052763893
- umap1_3d
- 1.44819344
- umap2_3d
- -1.53958654
- umap3_3d
- -1.620218867
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.540
- IL6_JAK_STAT3_SIGNALING+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- INTERFERON_GAMMA_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.410
- INTERFERON_ALPHA_RESPONSE+0.380
- INFLAMMATORY_RESPONSE+0.320
- COAGULATION+0.300
- ESTROGEN_RESPONSE_LATE+0.270
- KRAS_SIGNALING_UP+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.490
- PROTEIN_SECRETION-0.390
- MYC_TARGETS_V1-0.360
- OXIDATIVE_PHOSPHORYLATION-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MTORC1_SIGNALING-0.270
- DNA_REPAIR-0.160
- PEROXISOME-0.150
- E2F_TARGETS-0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1168 | Med | Medulloblastoma | 0.905 |
| 2 | SRR615467 | GTEX | — | 0.903 |
| 3 | MDT-AP-1177 | Med | Medulloblastoma | 0.896 |
| 4 | SRR1465632 | GTEX | — | 0.895 |
| 5 | SRR1084484 | GTEX | — | 0.894 |
| 6 | BS_TA9WP4TH | Med | Medulloblastoma | 0.882 |
| 7 | TCGA-44-7672-01A-11R-2066-07 | — | cohortA1 | 0.881 |
| 8 | BS_JBGZ7HHZ | ganglioneuroblastoma | — | 0.880 |
| 9 | MDT-AP-3331 | Med | Medulloblastoma | 0.880 |
| 10 | SRR615934 | GTEX | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |